Semaglutide Weight Loss Injections: How the Shot Works

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide is part of the PlexusDx Education Hub, where we translate GLP-1 therapies, longevity peptides, and metabolic science into decisions you can actually use. Explore the full Peptides & GLP-1 library.

If you have searched for semaglutide as a weight loss injection, you are really asking two things at once: what the shot does inside the body, and whether the results people describe hold up. This page walks the mechanism first, then the published evidence, the approved uses, the warnings worth taking seriously, and finally the genetic layer that sits underneath any appetite decision.

Why semaglutide is given as an injection

Semaglutide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist. When it binds the GLP-1 receptor it slows how quickly the stomach empties, softens the glucose rise that follows a meal, and amplifies satiety signaling in the hypothalamus. The practical result for many people is that meals feel filling sooner and post-meal blood sugar stays steadier. Delivering the molecule by injection is simply the route that keeps it active in circulation for that signaling to occur.

What the clinical programs actually measured

Semaglutide was studied across the SUSTAIN, STEP, and PIONEER trial programs. Reported average weight change differed by compound, dose, and the population enrolled, landing in the published literature somewhere in the range of five to twenty-two percent of baseline body weight at each study's endpoint. Those are trial averages drawn from the manuscripts and FDA labeling, not a promise attached to any one person's result.

Approved indications and why the label is the anchor

The FDA has cleared semaglutide for type 2 diabetes, first as Ozempic in 2017 and later as oral Rybelsus in 2019, and for chronic weight management as Wegovy in 2021. The approved label is the controlling reference for indications, dosing, contraindications, and warnings. Off-label use does happen in clinical practice; when it does, it rests on prescriber judgment rather than on any marketing claim.

Side effects, the boxed warning, and who should steer clear

The most common complaints are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. More serious events reported with semaglutide include pancreatitis, gallbladder problems, and acute kidney injury. The label also carries a boxed warning tied to thyroid C-cell tumors seen in rodent studies, and the drug should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Bring your full history to a qualified clinician before starting any GLP-1 pathway protocol.

Where your genetics enter the GLP-1 picture

Appetite and energy balance are not identical from one person to the next, and part of that difference is written in genes such as FTO, GLP1R, MC4R, and TCF7L2. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across those signaling systems. It does not predict how you will respond to semaglutide and it never sets a dose; it maps the baseline terrain so your provider conversation starts from data instead of guesswork. PlexusDx offers semaglutide through its Weight Management Protocols, available as a Semaglutide Injection or as oral semaglutide. Testing the biology before you invest in a protocol is the approach we favor.

What the trajectory really depends on

It helps to separate what the injection does from what determines your path. The GLP-1 mechanism changes satiety and gastric emptying, which lowers caloric intake for many people, but the trial figures are population averages rather than a personal forecast. The full clinical picture, consistency with the plan, and the everyday food and activity environment around the injection all shape how a given person progresses. None of that is captured by a single percentage.

The approved label defines who qualifies and how semaglutide is used, and a clinician decides whether an approved indication fits your situation. If a personal or family history raises the boxed-warning concerns, that conversation changes entirely. This page is educational context, not medical advice, and it is meant to help you arrive at a provider appointment already understanding the mechanism, the evidence, and the questions worth asking.

Frequently Asked Questions

How does the injection actually reduce appetite?

By activating the GLP-1 receptor, semaglutide slows gastric emptying and strengthens satiety signals in the brain, so fullness arrives with less food. It also steadies post-meal glucose. The size of the effect varies by person; trial averages from the SUSTAIN, STEP, and PIONEER programs describe populations, not guaranteed individual outcomes.

Is semaglutide FDA approved for weight loss?

Yes, in a specific form. Semaglutide is approved for type 2 diabetes as Ozempic and Rybelsus, and for chronic weight management as Wegovy in 2021. The approved label defines who qualifies and how it is used. A clinician determines whether an approved indication fits your situation.

Who should not use semaglutide injections?

Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 should avoid it, per the boxed warning. Caution also applies with a history of pancreatitis or certain kidney concerns. The complete contraindication list lives in the FDA label; review it with your provider.

Does a genetic test tell me my dose?

No. The Precision Peptide Genetic Test never predicts drug response or assigns a dose. It reads pathway-level variants such as FTO, GLP1R, and MC4R that shape baseline appetite and energy-balance biology, giving you and your provider upstream context for the broader protocol discussion.

Keep reading across the PlexusDx Education Hub for more on peptides, metabolism, and the genetics beneath them. Return to the Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.